Ever been in a meeting where someone casually suggests "Oh, we'll just build our own LIMS" and you're thinking "Do you have ANY idea what you just said?" This episode is for you.

Peter Ferreira breaks down the million-dollar question every biotech company faces: when to build custom solutions versus when to just buy existing tools and focus on the science that actually matters.

Through the cautionary tale of Sarah's $3M custom LIMS disaster (spoiler: her competitor beat her to market by 18 months using off-the-shelf software), you'll learn a practical framework for making build-vs-buy decisions that could save your company millions and keep you focused on breakthrough discoveries instead of debugging barcode scanners.

Whether you're a biotech CTO trying to balance innovation with compliance, a founder wondering if you should build your own clinical trial platform, or a technical leader tired of reinventing wheels while competitors race ahead, this episode gives you the strategic clarity to make smart technology decisions when lives depend on it.

What You'll Learn:

• The "Is This Actually Our Superpower?" framework for build-vs-buy decisions
• Why regulatory compliance changes everything (and why your weekend dashboard won't cut it)
• Real cost breakdowns that include the hidden expenses everyone forgets
• How to integrate commercial platforms with your proprietary science
• The one question that cuts through all the noise and saves you from expensive mistakes

No jargon, no BS, just practical advice from someone who's seen biotech companies succeed and fail based on these exact decisions.

#Biotech #CTO #TechnicalDueDiligence #BuildVsBuy #LIMS #Startups #BiotechCTO #TechStrategy #RegulatoryCompliance #LifeSciences #SoftwareDecisions #TechLeadership #DrugDevelopment #BiotechFounders #FDA #GxP #ClinicalTrials #LabTech #BiotechPodcast #TechManagement #Innovation #21CFRPart11 #BioPharma #MedTech #TechInvestment #ProductStrategy #EngineeringManagement #BiotechEntrepreneur #TechStack